- Home
- EMF vs ANL Comparison
EMF vs ANL Comparison
Compare EMF & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | EMF | ANL |
|---|---|---|
| Founded | 1987 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.7M | 350.9M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | EMF | ANL |
|---|---|---|
| Price | $19.20 | $8.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 59.8K | ★ 419.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 6.16% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.14 | $0.88 |
| 52 Week High | $21.20 | $12.09 |
Technical Indicators
Market Signals| Indicator | EMF | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 41.03 | 52.65 |
| Support Level | $16.13 | $1.36 |
| Resistance Level | $20.30 | $10.15 |
| Average True Range (ATR) | 0.39 | 0.86 |
| MACD | -0.21 | -0.49 |
| Stochastic Oscillator | 19.04 | 36.05 |
Price Performance
Historical ComparisonAbout EMF Templeton Emerging Markets Fund
Templeton Emerging Markets Fund is a closed-end management investment company that seeks long-term capital appreciation by investing mainly in emerging country equity securities under normal market conditions. It invests across various sectors, including Pharmaceuticals, Beverages, Broadline Retail, Metals & Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, Insurance, Entertainment, and others.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.